within Pharmacolibrary.Drugs.ATC.G;

model G02AD03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.1111111111111112e-05,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Gemeprost</td></tr><tr><td>ATC code:</td><td>G02AD03</td></tr><td>route:</td><td>vaginal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Gemeprost is a synthetic methyl ester analogue of prostaglandin E1 used primarily as a vaginal suppository for cervical ripening and to induce abortion or manage miscarriage. It has been used in obstetrics and gynecology, but its use is limited today with preference for other prostaglandins. It is not widely approved or available in most countries currently.</p><h4>Pharmacokinetics</h4><p>No human pharmacokinetic data are available in published literature for gemeprost. Estimated values are based on its class similarity with other prostaglandin E1 analogues used by vaginal administration.</p><h4>References</h4><ol><li><p>Avrech, OM, et al., &amp; Caspi, E (1991). Mifepristone (RU486) alone or in combination with a prostaglandin analogue for termination of early pregnancy: a review. <i>Fertility and sterility</i> 56(3) 385â€“393. DOI:<a href=\"https://doi.org/10.1016/s0015-0282(16)54527-0\">10.1016/s0015-0282(16)54527-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1894013/\">https://pubmed.ncbi.nlm.nih.gov/1894013</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end G02AD03;
